KLOW for Eyes: What the Evidence Shows
What human and animal studies show about KLOW for eyes, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- from an ingredient's studies
- Human studies
- 2
- with an outcome for eyes, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 2
- with an outcome for eyes, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 4
- with an outcome for eyes
Evidence for eyes
Each row is an outcome related to eyes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here. No study has tested KLOW itself; rows are for each ingredient.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| TB-500: Ocular discomfort and corneal staining | At day 56, the treated group had a 35.1% greater reduction in ocular discomfort and a 59.1% greater reduction in total corneal fluorescein staining than vehicle (very small trial). | Human RCTn = 9 | Cornea 2015, PMID 25826322 |
| TB-500: Primary endpoints | Neither primary endpoint (ocular discomfort, inferior corneal staining) differed significantly between groups. | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| TB-500: Secondary endpoints | Discomfort scores in the challenge environment on day 28 were 27% lower than placebo (P=0.0244), a secondary endpoint. | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| TB-500: Corneal alkali burn | The peptide-containing hydrogel accelerated corneal epithelial regeneration and reduced inflammation in an alkali burn model; this is a formulation study. | Animal · human corneal cells in vitro plus an animal alkali burn model (species not stated in abstract) (not a human result) | ACS applied materials & interfaces 2025, PMID 41359360 |
| BPC-157: Intraocular pressure | All BPC 157 regimens (eye drops, intraperitoneal, oral) normalized intraocular pressure in this rat glaucoma model. | Animal · rat (not a human result) | Biomedicines 2021, PMID 35052769 |
KLOW and eyes are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Eye care, briefly
MedlinePlus describes eye care as habits, checkups and treatment when needed, which is the frame for the eye outcomes below.[5]
Eye outcomes measured for the components of the four-peptide blend
The BPC-157 component was given as eye drops, by injection or in drinking water to rats with a glaucoma model; the abstract also reports preserved ganglion cells.[4]
A hydrogel built on the TB500 sequence promoted movement and growth of human corneal cells in the lab.[3]
Thymosin beta-4 drops (RGN-259) were examined in a phase 2 trial that reported a reduction in total corneal fluorescein staining versus vehicle; this trial involved a different product from TB-500.[1]
In a dry-eye challenge trial of the thymosin beta-4 solution (not TB-500), discomfort scores on day 28 were reduced by 27%.[2]
A PubMed search for all four components of this blend together returned 0 records on 2 Oct 2026, so no study has tested the blend on the eye.
Calculated from search GHK-Cu terms AND BPC-157 terms AND (TB-500 OR thymosin beta-4 terms) AND KPV terms; date 2026-10-02; count 0; page topic eyes; source our combinations data ghk-cu__klow. Formula: records matching all four components = count = 0
Other peptides people research for eyes
All peptides for eyes, comparedCommon questions
Does KLOW help with eyes?
The strongest study we summarise for eyes is human rct evidence, for an ingredient rather than the blend, across 4 studies with an outcome for eyes. A trial result is not an approval; see the legal status.
Is KLOW approved for eyes?
No. KLOW is not FDA approved for any use, including eyes.
What is the best peptide for eyes?
There is no single answer. Our eyes overview compares each candidate by evidence grade and legal status rather than by popularity.
Does KLOW help dry eye or glaucoma?
The glaucoma result is for BPC-157 alone in rats, and the dry-eye trials used thymosin beta-4 drops.[4]
More on KLOW
Sources
- 1Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 2Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.Clinical ophthalmology (Auckland, N.Z.) · 2015PMID 26056426Accessed 2 Oct 2026
- 3Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.ACS applied materials & interfaces · 2025PMID 41359360Accessed 2 Oct 2026
- 4Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.Biomedicines · 2021PMID 35052769Accessed 2 Oct 2026
- 5Official web pageOfficial web page · web page
Found an error? Report a correction.